FluoGuide A/S (FLUO.ST)
- Previous Close
39.60 - Open
39.20 - Bid 39.50 x --
- Ask 39.90 x --
- Day's Range
39.20 - 40.00 - 52 Week Range
29.10 - 57.00 - Volume
3,928 - Avg. Volume
6,227 - Market Cap (intraday)
543.442M - Beta (5Y Monthly) 1.24
- PE Ratio (TTM)
-- - EPS (TTM)
-3.27 - Earnings Date May 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
126.98
FluoGuide A/S, a clinical stage biotechnology company, focuses on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. FluoGuide A/S was incorporated in 2018 and is headquartered in Copenhagen, Denmark.
fluoguide.comRecent News: FLUO.ST
View MorePerformance Overview: FLUO.ST
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FLUO.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FLUO.ST
View MoreValuation Measures
Market Cap
543.44M
Enterprise Value
517.07M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
16.07
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-71.22%
Return on Equity (ttm)
-161.84%
Revenue (ttm)
385k
Net Income Avi to Common (ttm)
-28.96M
Diluted EPS (ttm)
-3.27
Balance Sheet and Cash Flow
Total Cash (mrq)
18.61M
Total Debt/Equity (mrq)
2.70%
Levered Free Cash Flow (ttm)
-21.75M